nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ORM1—Vismodegib—skin cancer	0.219	0.255	CbGbCtD
Canagliflozin—ORM1—Vemurafenib—skin cancer	0.173	0.201	CbGbCtD
Canagliflozin—ALB—Vismodegib—skin cancer	0.0923	0.107	CbGbCtD
Canagliflozin—ALB—Vemurafenib—skin cancer	0.0729	0.0847	CbGbCtD
Canagliflozin—ABCB1—Vismodegib—skin cancer	0.0483	0.0561	CbGbCtD
Canagliflozin—CYP3A4—Temozolomide—skin cancer	0.0417	0.0485	CbGbCtD
Canagliflozin—CYP3A4—Imiquimod—skin cancer	0.0417	0.0485	CbGbCtD
Canagliflozin—ABCC2—Docetaxel—skin cancer	0.0402	0.0467	CbGbCtD
Canagliflozin—ALB—Fluorouracil—skin cancer	0.0328	0.0381	CbGbCtD
Canagliflozin—CYP3A4—Vismodegib—skin cancer	0.0289	0.0336	CbGbCtD
Canagliflozin—ABCB1—Dactinomycin—skin cancer	0.0254	0.0295	CbGbCtD
Canagliflozin—CYP3A4—Vemurafenib—skin cancer	0.0229	0.0266	CbGbCtD
Canagliflozin—Vulvitis—Imiquimod—skin cancer	0.0204	0.147	CcSEcCtD
Canagliflozin—ABCB1—Docetaxel—skin cancer	0.0131	0.0152	CbGbCtD
Canagliflozin—CYP3A4—Docetaxel—skin cancer	0.00784	0.00911	CbGbCtD
Canagliflozin—Sunburn—Vemurafenib—skin cancer	0.00661	0.0474	CcSEcCtD
Canagliflozin—Rash papular—Vemurafenib—skin cancer	0.00536	0.0384	CcSEcCtD
Canagliflozin—Rash generalised—Vemurafenib—skin cancer	0.00469	0.0337	CcSEcCtD
Canagliflozin—Blood urea increased—Vismodegib—skin cancer	0.00305	0.0219	CcSEcCtD
Canagliflozin—Rash erythematous—Imiquimod—skin cancer	0.00222	0.0159	CcSEcCtD
Canagliflozin—Dehydration—Vismodegib—skin cancer	0.00218	0.0156	CcSEcCtD
Canagliflozin—Rash pustular—Imiquimod—skin cancer	0.00213	0.0153	CcSEcCtD
Canagliflozin—Breast disorder—Vismodegib—skin cancer	0.00212	0.0152	CcSEcCtD
Canagliflozin—Rash maculo-papular—Vemurafenib—skin cancer	0.00181	0.013	CcSEcCtD
Canagliflozin—Photosensitivity—Vemurafenib—skin cancer	0.00165	0.0118	CcSEcCtD
Canagliflozin—Vaginal infection—Imiquimod—skin cancer	0.00161	0.0115	CcSEcCtD
Canagliflozin—Rash generalised—Docetaxel—skin cancer	0.0016	0.0114	CcSEcCtD
Canagliflozin—Prurigo—Docetaxel—skin cancer	0.00147	0.0105	CcSEcCtD
Canagliflozin—Malnutrition—Vismodegib—skin cancer	0.00141	0.0101	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00119	0.00857	CcSEcCtD
Canagliflozin—Cystitis noninfective—Bleomycin—skin cancer	0.00118	0.00847	CcSEcCtD
Canagliflozin—Cystitis—Bleomycin—skin cancer	0.00117	0.00838	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Vemurafenib—skin cancer	0.00114	0.0082	CcSEcCtD
Canagliflozin—Nervous system disorder—Vismodegib—skin cancer	0.00113	0.00811	CcSEcCtD
Canagliflozin—Skin disorder—Vismodegib—skin cancer	0.00112	0.00803	CcSEcCtD
Canagliflozin—Breast disorder—Imiquimod—skin cancer	0.00112	0.00801	CcSEcCtD
Canagliflozin—Bladder pain—Bleomycin—skin cancer	0.00109	0.00784	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Vismodegib—skin cancer	0.000995	0.00714	CcSEcCtD
Canagliflozin—Fatigue—Vismodegib—skin cancer	0.000994	0.00713	CcSEcCtD
Canagliflozin—Constipation—Vismodegib—skin cancer	0.000986	0.00707	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Imiquimod—skin cancer	0.000975	0.00699	CcSEcCtD
Canagliflozin—Vaginal infection—Temozolomide—skin cancer	0.000963	0.00691	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vismodegib—skin cancer	0.000942	0.00676	CcSEcCtD
Canagliflozin—Urinary tract infection—Imiquimod—skin cancer	0.000926	0.00664	CcSEcCtD
Canagliflozin—Abdominal pain—Vismodegib—skin cancer	0.000911	0.00654	CcSEcCtD
Canagliflozin—Angiopathy—Vemurafenib—skin cancer	0.000909	0.00652	CcSEcCtD
Canagliflozin—Rash erythematous—Docetaxel—skin cancer	0.000886	0.00636	CcSEcCtD
Canagliflozin—Malnutrition—Vemurafenib—skin cancer	0.000872	0.00626	CcSEcCtD
Canagliflozin—Erythema—Vemurafenib—skin cancer	0.000872	0.00626	CcSEcCtD
Canagliflozin—Rash maculo-papular—Fluorouracil—skin cancer	0.000854	0.00613	CcSEcCtD
Canagliflozin—Urinary tract disorder—Imiquimod—skin cancer	0.000844	0.00606	CcSEcCtD
Canagliflozin—Urethral disorder—Imiquimod—skin cancer	0.000838	0.00601	CcSEcCtD
Canagliflozin—Asthenia—Vismodegib—skin cancer	0.000827	0.00593	CcSEcCtD
Canagliflozin—Pruritus—Vismodegib—skin cancer	0.000815	0.00585	CcSEcCtD
Canagliflozin—Thirst—Temozolomide—skin cancer	0.000778	0.00558	CcSEcCtD
Canagliflozin—Photosensitivity—Fluorouracil—skin cancer	0.000777	0.00557	CcSEcCtD
Canagliflozin—Angiopathy—Imiquimod—skin cancer	0.000775	0.00556	CcSEcCtD
Canagliflozin—Malnutrition—Imiquimod—skin cancer	0.000744	0.00534	CcSEcCtD
Canagliflozin—Erythema—Imiquimod—skin cancer	0.000744	0.00534	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000738	0.00529	CcSEcCtD
Canagliflozin—Rash—Vismodegib—skin cancer	0.000727	0.00521	CcSEcCtD
Canagliflozin—Dermatitis—Vismodegib—skin cancer	0.000726	0.00521	CcSEcCtD
Canagliflozin—Infection—Vemurafenib—skin cancer	0.000707	0.00508	CcSEcCtD
Canagliflozin—Nervous system disorder—Vemurafenib—skin cancer	0.000698	0.00501	CcSEcCtD
Canagliflozin—Skin disorder—Vemurafenib—skin cancer	0.000692	0.00496	CcSEcCtD
Canagliflozin—Dehydration—Temozolomide—skin cancer	0.000689	0.00494	CcSEcCtD
Canagliflozin—Nausea—Vismodegib—skin cancer	0.000685	0.00491	CcSEcCtD
Canagliflozin—Angioedema—Imiquimod—skin cancer	0.00068	0.00488	CcSEcCtD
Canagliflozin—Breast disorder—Temozolomide—skin cancer	0.000669	0.0048	CcSEcCtD
Canagliflozin—Syncope—Imiquimod—skin cancer	0.000667	0.00479	CcSEcCtD
Canagliflozin—Hypotension—Vemurafenib—skin cancer	0.000665	0.00477	CcSEcCtD
Canagliflozin—Loss of consciousness—Imiquimod—skin cancer	0.000654	0.00469	CcSEcCtD
Canagliflozin—Convulsion—Imiquimod—skin cancer	0.000645	0.00463	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000629	0.00451	CcSEcCtD
Canagliflozin—Dry mouth—Imiquimod—skin cancer	0.00062	0.00445	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000615	0.00441	CcSEcCtD
Canagliflozin—Fatigue—Vemurafenib—skin cancer	0.000614	0.0044	CcSEcCtD
Canagliflozin—Constipation—Vemurafenib—skin cancer	0.000609	0.00437	CcSEcCtD
Canagliflozin—Infection—Imiquimod—skin cancer	0.000603	0.00433	CcSEcCtD
Canagliflozin—Shock—Imiquimod—skin cancer	0.000597	0.00429	CcSEcCtD
Canagliflozin—Nervous system disorder—Imiquimod—skin cancer	0.000596	0.00427	CcSEcCtD
Canagliflozin—Pollakiuria—Temozolomide—skin cancer	0.000591	0.00424	CcSEcCtD
Canagliflozin—Skin disorder—Imiquimod—skin cancer	0.00059	0.00423	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Temozolomide—skin cancer	0.000584	0.00419	CcSEcCtD
Canagliflozin—Urinary tract infection—Temozolomide—skin cancer	0.000555	0.00398	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Fluorouracil—skin cancer	0.000538	0.00386	CcSEcCtD
Canagliflozin—Erythema—Bleomycin—skin cancer	0.000529	0.00379	CcSEcCtD
Canagliflozin—Hypersensitivity—Vemurafenib—skin cancer	0.000525	0.00376	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Imiquimod—skin cancer	0.000524	0.00376	CcSEcCtD
Canagliflozin—Fatigue—Imiquimod—skin cancer	0.000524	0.00376	CcSEcCtD
Canagliflozin—Urinary tract infection—Fluorouracil—skin cancer	0.000511	0.00367	CcSEcCtD
Canagliflozin—Asthenia—Vemurafenib—skin cancer	0.000511	0.00367	CcSEcCtD
Canagliflozin—Urinary tract disorder—Temozolomide—skin cancer	0.000506	0.00363	CcSEcCtD
Canagliflozin—Pruritus—Vemurafenib—skin cancer	0.000504	0.00361	CcSEcCtD
Canagliflozin—Urethral disorder—Temozolomide—skin cancer	0.000502	0.0036	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Imiquimod—skin cancer	0.000497	0.00356	CcSEcCtD
Canagliflozin—Erythema—Dactinomycin—skin cancer	0.000493	0.00354	CcSEcCtD
Canagliflozin—Urticaria—Imiquimod—skin cancer	0.000482	0.00346	CcSEcCtD
Canagliflozin—Abdominal pain—Imiquimod—skin cancer	0.00048	0.00344	CcSEcCtD
Canagliflozin—Dizziness—Vemurafenib—skin cancer	0.000471	0.00338	CcSEcCtD
Canagliflozin—Angiopathy—Temozolomide—skin cancer	0.000465	0.00333	CcSEcCtD
Canagliflozin—Dehydration—Docetaxel—skin cancer	0.000458	0.00329	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Docetaxel—skin cancer	0.00045	0.00323	CcSEcCtD
Canagliflozin—Rash—Vemurafenib—skin cancer	0.000449	0.00322	CcSEcCtD
Canagliflozin—Dermatitis—Vemurafenib—skin cancer	0.000449	0.00322	CcSEcCtD
Canagliflozin—Hypersensitivity—Imiquimod—skin cancer	0.000447	0.00321	CcSEcCtD
Canagliflozin—Malnutrition—Temozolomide—skin cancer	0.000446	0.0032	CcSEcCtD
Canagliflozin—Erythema—Temozolomide—skin cancer	0.000446	0.0032	CcSEcCtD
Canagliflozin—Breast disorder—Docetaxel—skin cancer	0.000445	0.00319	CcSEcCtD
Canagliflozin—Asthenia—Imiquimod—skin cancer	0.000436	0.00313	CcSEcCtD
Canagliflozin—Pruritus—Imiquimod—skin cancer	0.00043	0.00308	CcSEcCtD
Canagliflozin—Infection—Bleomycin—skin cancer	0.000429	0.00308	CcSEcCtD
Canagliflozin—Nausea—Vemurafenib—skin cancer	0.000423	0.00303	CcSEcCtD
Canagliflozin—Erythema—Fluorouracil—skin cancer	0.000411	0.00295	CcSEcCtD
Canagliflozin—Angioedema—Temozolomide—skin cancer	0.000407	0.00292	CcSEcCtD
Canagliflozin—Hypotension—Bleomycin—skin cancer	0.000403	0.00289	CcSEcCtD
Canagliflozin—Dizziness—Imiquimod—skin cancer	0.000402	0.00288	CcSEcCtD
Canagliflozin—Infection—Dactinomycin—skin cancer	0.0004	0.00287	CcSEcCtD
Canagliflozin—Convulsion—Temozolomide—skin cancer	0.000386	0.00277	CcSEcCtD
Canagliflozin—Rash—Imiquimod—skin cancer	0.000383	0.00275	CcSEcCtD
Canagliflozin—Dermatitis—Imiquimod—skin cancer	0.000383	0.00274	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000377	0.00271	CcSEcCtD
Canagliflozin—Dry mouth—Temozolomide—skin cancer	0.000371	0.00266	CcSEcCtD
Canagliflozin—Infection—Temozolomide—skin cancer	0.000362	0.00259	CcSEcCtD
Canagliflozin—Nausea—Imiquimod—skin cancer	0.000361	0.00259	CcSEcCtD
Canagliflozin—Nervous system disorder—Temozolomide—skin cancer	0.000357	0.00256	CcSEcCtD
Canagliflozin—Convulsion—Fluorouracil—skin cancer	0.000356	0.00255	CcSEcCtD
Canagliflozin—Skin disorder—Temozolomide—skin cancer	0.000353	0.00254	CcSEcCtD
Canagliflozin—Fatigue—Dactinomycin—skin cancer	0.000347	0.00249	CcSEcCtD
Canagliflozin—Urticaria—Bleomycin—skin cancer	0.000343	0.00246	CcSEcCtD
Canagliflozin—Urinary tract disorder—Docetaxel—skin cancer	0.000336	0.00241	CcSEcCtD
Canagliflozin—Urethral disorder—Docetaxel—skin cancer	0.000334	0.0024	CcSEcCtD
Canagliflozin—Infection—Fluorouracil—skin cancer	0.000333	0.00239	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dactinomycin—skin cancer	0.000329	0.00236	CcSEcCtD
Canagliflozin—Nervous system disorder—Fluorouracil—skin cancer	0.000329	0.00236	CcSEcCtD
Canagliflozin—Abdominal pain—Dactinomycin—skin cancer	0.000318	0.00228	CcSEcCtD
Canagliflozin—Hypersensitivity—Bleomycin—skin cancer	0.000318	0.00228	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Temozolomide—skin cancer	0.000314	0.00225	CcSEcCtD
Canagliflozin—Fatigue—Temozolomide—skin cancer	0.000314	0.00225	CcSEcCtD
Canagliflozin—Hypotension—Fluorouracil—skin cancer	0.000313	0.00225	CcSEcCtD
Canagliflozin—Constipation—Temozolomide—skin cancer	0.000311	0.00223	CcSEcCtD
Canagliflozin—Asthenia—Bleomycin—skin cancer	0.00031	0.00222	CcSEcCtD
Canagliflozin—Angiopathy—Docetaxel—skin cancer	0.000309	0.00222	CcSEcCtD
Canagliflozin—Pruritus—Bleomycin—skin cancer	0.000305	0.00219	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Temozolomide—skin cancer	0.000298	0.00214	CcSEcCtD
Canagliflozin—Malnutrition—Docetaxel—skin cancer	0.000297	0.00213	CcSEcCtD
Canagliflozin—Erythema—Docetaxel—skin cancer	0.000297	0.00213	CcSEcCtD
Canagliflozin—Hypersensitivity—Dactinomycin—skin cancer	0.000296	0.00213	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000289	0.00208	CcSEcCtD
Canagliflozin—Urticaria—Temozolomide—skin cancer	0.000289	0.00207	CcSEcCtD
Canagliflozin—Asthenia—Dactinomycin—skin cancer	0.000289	0.00207	CcSEcCtD
Canagliflozin—Abdominal pain—Temozolomide—skin cancer	0.000288	0.00206	CcSEcCtD
Canagliflozin—Rash—Bleomycin—skin cancer	0.000272	0.00195	CcSEcCtD
Canagliflozin—Dermatitis—Bleomycin—skin cancer	0.000272	0.00195	CcSEcCtD
Canagliflozin—Hypersensitivity—Temozolomide—skin cancer	0.000268	0.00192	CcSEcCtD
Canagliflozin—Urticaria—Fluorouracil—skin cancer	0.000266	0.00191	CcSEcCtD
Canagliflozin—Syncope—Docetaxel—skin cancer	0.000266	0.00191	CcSEcCtD
Canagliflozin—Asthenia—Temozolomide—skin cancer	0.000261	0.00187	CcSEcCtD
Canagliflozin—Loss of consciousness—Docetaxel—skin cancer	0.000261	0.00187	CcSEcCtD
Canagliflozin—Pruritus—Temozolomide—skin cancer	0.000257	0.00185	CcSEcCtD
Canagliflozin—Convulsion—Docetaxel—skin cancer	0.000257	0.00184	CcSEcCtD
Canagliflozin—Nausea—Bleomycin—skin cancer	0.000256	0.00184	CcSEcCtD
Canagliflozin—Rash—Dactinomycin—skin cancer	0.000254	0.00182	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000251	0.0018	CcSEcCtD
Canagliflozin—Hypersensitivity—Fluorouracil—skin cancer	0.000247	0.00177	CcSEcCtD
Canagliflozin—Dry mouth—Docetaxel—skin cancer	0.000247	0.00177	CcSEcCtD
Canagliflozin—Dizziness—Temozolomide—skin cancer	0.000241	0.00173	CcSEcCtD
Canagliflozin—Infection—Docetaxel—skin cancer	0.00024	0.00173	CcSEcCtD
Canagliflozin—Nausea—Dactinomycin—skin cancer	0.000239	0.00171	CcSEcCtD
Canagliflozin—Shock—Docetaxel—skin cancer	0.000238	0.00171	CcSEcCtD
Canagliflozin—Nervous system disorder—Docetaxel—skin cancer	0.000237	0.0017	CcSEcCtD
Canagliflozin—Pruritus—Fluorouracil—skin cancer	0.000237	0.0017	CcSEcCtD
Canagliflozin—Skin disorder—Docetaxel—skin cancer	0.000235	0.00169	CcSEcCtD
Canagliflozin—Rash—Temozolomide—skin cancer	0.000229	0.00165	CcSEcCtD
Canagliflozin—Dermatitis—Temozolomide—skin cancer	0.000229	0.00164	CcSEcCtD
Canagliflozin—Hypotension—Docetaxel—skin cancer	0.000226	0.00162	CcSEcCtD
Canagliflozin—Dizziness—Fluorouracil—skin cancer	0.000222	0.00159	CcSEcCtD
Canagliflozin—Nausea—Temozolomide—skin cancer	0.000216	0.00155	CcSEcCtD
Canagliflozin—Rash—Fluorouracil—skin cancer	0.000211	0.00152	CcSEcCtD
Canagliflozin—Dermatitis—Fluorouracil—skin cancer	0.000211	0.00152	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Docetaxel—skin cancer	0.000209	0.0015	CcSEcCtD
Canagliflozin—Fatigue—Docetaxel—skin cancer	0.000209	0.0015	CcSEcCtD
Canagliflozin—Constipation—Docetaxel—skin cancer	0.000207	0.00148	CcSEcCtD
Canagliflozin—Nausea—Fluorouracil—skin cancer	0.000199	0.00143	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Docetaxel—skin cancer	0.000198	0.00142	CcSEcCtD
Canagliflozin—Abdominal pain—Docetaxel—skin cancer	0.000191	0.00137	CcSEcCtD
Canagliflozin—Hypersensitivity—Docetaxel—skin cancer	0.000178	0.00128	CcSEcCtD
Canagliflozin—Asthenia—Docetaxel—skin cancer	0.000174	0.00125	CcSEcCtD
Canagliflozin—Pruritus—Docetaxel—skin cancer	0.000171	0.00123	CcSEcCtD
Canagliflozin—Dizziness—Docetaxel—skin cancer	0.00016	0.00115	CcSEcCtD
Canagliflozin—Rash—Docetaxel—skin cancer	0.000153	0.00109	CcSEcCtD
Canagliflozin—Dermatitis—Docetaxel—skin cancer	0.000152	0.00109	CcSEcCtD
Canagliflozin—Nausea—Docetaxel—skin cancer	0.000144	0.00103	CcSEcCtD
